Citations

Clear

1011 citation(s) found for "Barry, WT".

Personalized Management of Chemotherapy‐Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance)
Mehrotra, Shailly , Gray, Elizabeth, Wu, Kehua, Barry, William T., Hudis, Clifford A. , Lyss, Alan P., Toppmeyer, Deborah , Moreno‐Aspitia, Alvaro , Lad, Thomas E. , Velasco, Mario R. , Overmoyer, Beth , Ratain, Mark J. , Sharma, Manish R. , Gray, Elizabeth, Winer, Eric P. , Rugo, Hope S. , Gobburu, Jogarao , Sharma, Manish R.

Mayo Clinic

The Journal of Clinical Pharmacology | December 5, 2019 | Volume: 60 | Issue: 4 | Pages: 444-452

10.1002/jcph.1559 | PMID 31802506 Get It

AbstractChemotherapy‐induced peripheral neuropathy (henceforth, neuropathy) is often dose limiting and is generally managed by empirical dose modifications. We aimed to (1) identify an early time point that is predictive of future neuropathy using a patient‐reported outcome and (2) propose a dose‐adjustment algorithm based on simulated data to manage neuropathy. In previous work, a dose‐neuropathy model was developed using dosing and patient‐reported outcome data from Cancer and Leukemia Group B 40502 (Alliance), a randomized phase III trial of paclitaxel, nanoparticle albumin–bound paclitaxel or ixabepilone as first‐line chemotherapy for locally recurrent or metastatic breast cancer. In the current work, an early time point that is predictive of the future severity of neuropathy was identified based on predictive accuracy of the model. Using the early data and model parameters, simulations were conducted to propose a dose‐adjustment algorithm for the prospective management of neuropathy in individual patients. The end of the first 3 cycles (12 weeks) was identified as the early time point based on a predictive accuracy of 75% for the neuropathy score after 6 cycles. For paclitaxel, nanoparticle albumin–bound paclitaxel, and ixabepilone, simulations with the proposed dose‐adjustment algorithm resulted in 61%, 48%, and 35% fewer patients, respectively, with neuropathy score ≥8 after 6 cycles compared to no dose adjustment. We conclude that early patient‐reported outcome data on neuropathy can be used to guide dose adjustments in individual patients that reduce the severity of future neuropathy. Prospective validation of this approach should be undertaken in future studies.
Atrial Fibrillation: Thinking Beyond Thromboembolism
Reddy, Yogesh N.V. , Nishimura, Rick , Borlaug, Barry A.

Mayo Clinic

European Journal of Heart Failure | November 27, 2019 | Volume: 21 | Issue: 12 | Pages: 1580-1583

10.1002/ejhf.1683 | PMID 31777151 Get It

Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement on Perioperative Smoking Cessation
An, Dong Ai , Tønnesen, Hanne , Raveendran, Raviraj, Abdullah, Hairil Rizal , Pfeifer, Kurt , Maa, John, Finegan, Barry A. , Li, Emily, Webb, Ashley , Edwards, Angela F., Preston, Paul, Bentov, Nathalie , Richman, Deborah C. , Wong, Jean , Urman, Richard D , Warner, David O. , Chung, Frances

Mayo Clinic

Anesthesia & Analgesia | November 25, 2019 | Volume: 131 | Issue: 3 | Pages: 955-968

10.1213/ane.0000000000004508 | PMID 31764157 Get It

Smokers are at increased risk for surgical complications. Despite the known benefits of smoking cessation, many perioperative health care providers do not routinely provide smoking cessation interventions. The variation in delivery of perioperative smoking cessation interventions may be due to limited high-level evidence for whether smoking cessation interventions used in the general population are effective and feasible in the surgical population, as well as the challenges and barriers to implementation of interventions. Yet smoking is a potentially modifiable risk factor for improving short- and long-term patient outcomes. The purpose of the Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement on Perioperative Smoking Cessation is to present recommendations based on current scientific evidence in surgical patients. These statements address questions regarding the timing and intensity of interventions, roles of perioperative health care providers, and behavioral and pharmacological interventions. Barriers and strategies to overcome challenges surrounding implementation of interventions and future areas of research are identified. These statements are based on the current state of knowledge and its interpretation by a multidisciplinary group of experts at the time of publication.
Letter by Reddy et al Regarding Article, “Effects of Arteriovenous Fistula Ligation on Cardiac Structure and Function in Kidney Transplant Recipients”
Reddy, Yogesh N.V. , Nath, Karl A. , Nishimura, Rick , Borlaug, Barry A.

Mayo Clinic

Circulation | November 18, 2019 | Volume: 140 | Issue: 21 | Pages: No page available

10.1161/circulationaha.119.042028 | PMID 31738600 Get It

Pathophysiologic and Prognostic Implications of Right Atrial Hypertension in Adults With Tetralogy of Fallot
Egbe, Alexander C. , Bonnichsen, Crystal R. , Reddy, Yogesh N.V. , Bonnichsen, Crystal, Anderson, Jason H. , Nishimura, Rick , Borlaug, Barry A.

Mayo Clinic

Journal of the American Heart Association | November 8, 2019 | Volume: 8 | Issue: 22 | Pages: No page available

10.1161/jaha.119.014148 | PMID 31701796 Get It

Background Right atrial pressure ( RAP ), a composite metric of right ventricular diastolic function, volume status, and right heart compliance, is a predictor of mortality in patients with heart failure due to acquired heart disease. Because patients with tetralogy of Fallot ( TOF ) might have abnormal right atrial and ventricular mechanics caused by myocardial injury and remodeling, we hypothesized that RAP would be associated with disease severity and cardiovascular adverse events in this population. Methods and Results We performed a cohort study of adults with TOF who underwent right heart catheterization at the Mayo Clinic Rochester between 1990 and 2017. The objective was to determine the association between RAP and multiple domains of disease severity in TOF (percentage of predicted peak oxygen consumption, atrial or ventricular arrhythmia, and heart failure hospitalization), as well as cardiovascular adverse events, defined as sustained ventricular tachycardia, resuscitated or aborted sudden death, heart transplantation, or death. Among 225 patients (113 male; mean age: 39±14 years), mean RAP was 10.7±5.2 mm Hg and median was 10 mm Hg (interquartile range: 7–13 mm Hg). Increasing RAP was associated with atrial or ventricular arrhythmias (odds ratio: 5.01; 95% CI, 1.22–23.49; P <0.001), heart failure hospitalization (odds ratio: 1.47; 95% CI, 1.10–2.39; P =0.033) per 5 mm Hg, and worsening exercise capacity (peak oxygen consumption; R 2 =0.74, r =−0.86, P <0.001). RAP was a predictor of cardiovascular adverse events (hazard ratio: 1.28; 95% CI, 1.10–1.47; P =0.028) per 5 mm Hg. Conclusions In symptomatic patients with TOF , increasing RAP correlates with multiple domains of disease severity (risk stratification) and predicts future cardiovascular events (prognostication). These data have potential clinical implications in the target population of symptomatic TOF patients.
Editorial: Merging therapeutics and supportive care: synergy and yield
Jatoi, Aminah , Laird, Barry

Mayo Clinic

Current Opinion in Supportive & Palliative Care | October 23, 2019 | Volume: 13 | Issue: 4 | Pages: 277-278

10.1097/spc.0000000000000468 | PMID 31644452 Get It

Comparison of Gene Delivery to the Kidney by Adenovirus, Adeno-Associated Virus, and Lentiviral Vectors After Intravenous and Direct Kidney Injections
Rubin, Jeffrey D. , Nguyen, Tien V., Allen, Kari L. , Ayasoufi, Katayoun , Barry, Michael A. , Barry, Michael A , Ayasoufi, Katayoun , Nguyen, Tien V.

Mayo Clinic

Human Gene Therapy | October 22, 2019 | Volume: 30 | Issue: 12 | Pages: 1559-1571

10.1089/hum.2019.127 | PMID 31637925 Get It

There are many kidney diseases that might be addressed by gene therapy. However, gene delivery to kidney cells is inefficient. This is due, in part, to the fact that the kidney excludes molecules above 50 kDa and that most gene delivery vectors are megaDaltons in mass. We compared the ability of adeno-associated virus (AAV), adenovirus (Ad), and lentiviral (LV) vectors to deliver genes to renal cells. When vectors were delivered by the intravenous (IV) route in mice, weak luciferase activity was observed in the kidney with substantially more in the liver. When gene delivery was observed in the kidney, expression was primarily in the glomerulus. To avoid these limitations, vectors were injected directly into the kidney by retrograde ureteral (RU) and subcapsular (SC) injections in mice. Small AAV vectors transduced the kidney, but also leaked from the organ and mediated higher levels of transduction in off-target tissues. Comparison of AAV2, 6.2, 8, and rh10 vectors by direct kidney injection demonstrated highest delivery by AAV6.2 and 8. Larger Ad and LV vectors transduced kidney cells and mediated less off-target tissue transduction. These data demonstrate the utility of direct kidney injections to circumvent the kidney size exclusion barrier. They also identify the effects of vector size on on-target and off-target transduction. This lays the foundation for the use of different vector platforms for gene therapy of diverse kidney diseases.
P323Haemodynamic implications of mitral regurgitation in heart failure with preserved ejection fraction
Delpon, M A Tamargo, Masaru, O, Egbe, Alexander C. , Reddy, Yogesh N.V. , Pislaru, Sorin V. , Borlaug, Barry A.

Mayo Clinic

European Heart Journal | October 21, 2019 | Volume: 40 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehz747.0158 Get It

Abstract Background Mild to moderate mitral regurgitation (MR) is a common finding in heart failure with preserved ejection fraction (HFpEF). MR is often considered to be an innocent bystander, yet little data is available regarding its implications. Aim Determine the pathophysiologic correlates of MR in HFpEF Methods We retrospectively studied 280 patients with invasively proven HFpEF. MR was absent (None or trivial) in 163 subjects (Non-MR-HFpEF), and present in 117 (MR-HFpEF; 78 mild and 39 moderate MR). 247 subjects also underwent invasive cardiopulmonary exercise testing. Results At rest, MR-HFpEF subjects displayed higher pulmonary artery pressures (PAP), PCWP, and pulmonary vascular resistance (PVR; Table). During exercise, PAP and PCWP were not significantly different among groups, but MR-HFpEF displayed reduced ability to enhance cardiac output (CO) in response to heightened metabolic demand (oxygen consumption, VO2; Figure). Baseline characteristics and haemodynamic characterization at baseline and peak exercise Baseline characteristics Non-MR-HFpEF (N=163) MR-HFpEF (N=117) p value Age 66±11 71±10 0.0002 Female (%) 56 69 0.02 AFib (%) 13 38 <0.0001 Nt proBNP 192 [66, 557] 870 [401, 2135] <0.0001 E/E' 12.3±5.5 15.6±7.2 0.0006 LVEF (%) 64±6 62±6 0.0001 RV fractional area change (%) 51±9 47±10 0.0001 Mean PA (mmHg) 25±7 28±9 0.001 Mean PCWP (mmHg) 15±5 17±6 0.0002 PVR (Woods) 2.0±1.1 2.5±1.4 0.015 CO (L/min) 5.5±1.6 4.8±1.3 0.12 Peak exercise hemodynamics Non-MR-HFpEF (N=152) MR-HFpEF (N=95) p value Mean PA (mmHg 45±10 46.5±10 0.07 Mean PCWP (mmHg) 32±6 31±6 0.6 PVR (Woods) 1.8±1.6 2.7±2.4 0.002 CO (L/min) 9.1±3 7.2±3 0.01 P value adjusted for age, gender and BMI. CO change in response to VO2 increase Conclusion The presence of even mild MR in HFpEF is associated with more adverse hemodynamics, greater pulmonary vascular dysfunction and impaired CO reserve with exercise. Further study is required to better understand the natural history and treatment for MR in HFpEF. Acknowledgement/Funding None